Research Analysts Set Expectations for Xencor Q2 Earnings

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Investment analysts at William Blair dropped their Q2 2025 earnings per share estimates for Xencor in a research report issued to clients and investors on Wednesday, May 7th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will earn ($0.87) per share for the quarter, down from their prior forecast of ($0.82). William Blair has a "Outperform" rating on the stock. The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. William Blair also issued estimates for Xencor's Q3 2025 earnings at ($0.89) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($3.33) EPS, Q1 2026 earnings at ($0.88) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.81) EPS, FY2026 earnings at ($3.32) EPS, FY2027 earnings at ($3.15) EPS and FY2028 earnings at ($3.24) EPS.

Several other research analysts have also recently issued reports on XNCR. Barclays dropped their price objective on Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research note on Thursday. Wells Fargo & Company dropped their price objective on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Wedbush reissued an "outperform" rating and issued a $31.00 price objective on shares of Xencor in a research note on Wednesday, April 30th. Finally, StockNews.com cut Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Two research analysts have rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Xencor has a consensus rating of "Moderate Buy" and an average price target of $29.50.

Xencor Trading Down 5.2%

Shares of NASDAQ XNCR opened at $8.33 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The business's 50 day moving average price is $10.73 and its 200-day moving average price is $17.61. Xencor has a fifty-two week low of $7.16 and a fifty-two week high of $27.24. The company has a market cap of $592.70 million, a price-to-earnings ratio of -2.60 and a beta of 0.99.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $32.73 million during the quarter, compared to analysts' expectations of $23.44 million. During the same quarter in the previous year, the company posted ($1.11) earnings per share. The company's quarterly revenue was up 104.6% compared to the same quarter last year.

Insider Buying and Selling at Xencor

In other Xencor news, EVP Nancy Valente sold 4,616 shares of the stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total transaction of $50,914.48. Following the sale, the executive vice president now owns 49,169 shares of the company's stock, valued at approximately $542,334.07. This trade represents a 8.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.76% of the company's stock.

Institutional Trading of Xencor

A number of institutional investors have recently made changes to their positions in XNCR. Sterling Capital Management LLC boosted its position in shares of Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Xencor in the 4th quarter worth $34,000. CWM LLC boosted its position in shares of Xencor by 195.5% in the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock worth $36,000 after purchasing an additional 2,231 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 508 shares in the last quarter. Finally, KBC Group NV boosted its position in shares of Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock worth $90,000 after purchasing an additional 813 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.